Skip to main content
. 2009 Nov;1(3):183–205. doi: 10.1177/1758834009349119

Table 6.

Randomized phase III trial of everolimus with best supportive care or placebo with best supportive care in metastatic renal cell cancer patients who have failed at least one vascular endothelial growth factor tyrosine kinase inhibitor [Motzer et al. 2008b].

Treatment PFS p value OS p value
Everolimus 4.0 0.0001 NR NA
Placebo 1.9 8.8

NR, not reached; OS, overall survival; PFS, progression-free survival.